PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27286707-0	2016	6-Shogaol has anti-amyloidogenic activity and ameliorates Alzheimer"s disease via CysLT1R-mediated inhibition of cathepsin B.	shogaol	0-9	cathepsin B	Mus musculus	113-124	
27286707-5	2016	We used in vitro and in vivo models to determine whether 6-shogaol inhibits CysLT1R/cathepsin B in an amyloid-beta (Abeta; 1-42)-induced model of neurotoxicity.	shogaol	57-66	cathepsin B	Mus musculus	84-95	
27286707-7	2016	In contrast, we found that 6-shogaol-mediated inhibition of CysLT1R downregulates cathepsin B in both in vitro and in vivo models.	shogaol	27-36	cathepsin B	Mus musculus	82-93	
27286707-8	2016	Furthermore, we found that 6-shogaol-mediated inhibition of CysLT1R/cathepsin B reduces Abeta deposition in the brain and ameliorates behavioral deficits in APPSw/PS1-dE9 Tg mice.	shogaol	27-36	cathepsin B	Mus musculus	68-79	
27286707-9	2016	Our results indicate that 6-shogaol is a CysLT1R/cathepsin B inhibitor and is a novel potential therapeutic agent for the treatment of various neurodegenerative diseases, including AD.	shogaol	26-35	cathepsin B	Mus musculus	49-60